Literature DB >> 11842317

Therapeutic significance of distal airway inflammation in asthma.

Richard J Martin1.   

Abstract

Inflammation in asthma is not merely confined to the large central airways but also extends to the small peripheral airways. Distal lung inflammation can be observed even in patients with asthma with mild disease and normal spirometric readings. Subjects with asymptomatic asthma can exhibit significant increases in peripheral airway resistance, likely the result of distal lung inflammation. As determined from measurements of eosinophilic and other cellular infiltrates, the inflammatory response in the distal lung can exceed that in the large airways. Nocturnal asthma, a natural model of cyclic asthma worsening, is associated with an increase in nighttime distal lung inflammation, as evidenced by the accumulation of alveolar tissue eosinophils. Distal lung disease appears to increase the risk of recurrent asthma exacerbation, whereas disease-related anatomic changes in the small airways of the distal lung are prominent in fatal asthma. The clinical significance of distal lung disease makes this region an important therapeutic target. Chlorofluorocarbon (CFC)-based preparations of inhaled corticosteroids used to treat airway inflammation produce aerosols of relatively large particle size (approximately 4 microm); such aerosols have poor access to the distal lung. New formulations of inhaled corticosteroids that use hydrofluoroalkane (HFA) propellants can have smaller particle sizes (approximately 1 microm). Extrafine HFA aerosols have better access to the distal lung, with less oropharyngeal deposition. Imaging studies suggest that anti-inflammatory medication delivered as an extrafine aerosol produces beneficial changes in distal lung function. In one study, an HFA formulation of an inhaled corticosteroid reduced air trapping to a greater degree than a CFC formulation of the same corticosteroid. By extending the delivery of anti-inflammatory medication to the distal lung, the new HFA-based corticosteroids have the potential to treat asthma more effectively and at reduced steroid doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11842317     DOI: 10.1067/mai.2002.121409

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

1.  Alveolar macrophages stimulate enhanced cytokine production by pulmonary CD4+ T-lymphocytes in an exacerbation of murine chronic asthma.

Authors:  Cristan Herbert; Melissa M Scott; Kim H Scruton; Rylie P Keogh; Kristy C Yuan; Kenneth Hsu; Jessica S Siegle; Nicodemus Tedla; Paul S Foster; Rakesh K Kumar
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

Review 2.  Particle size analysis in pharmaceutics: principles, methods and applications.

Authors:  Boris Y Shekunov; Pratibhash Chattopadhyay; Henry H Y Tong; Albert H L Chow
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

Review 3.  Pediatric exercise-induced bronchoconstriction: contemporary developments in epidemiology, pathogenesis, presentation, diagnosis, and therapy.

Authors:  Christopher Randolph
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

4.  Contractility and Ca2+ signaling of smooth muscle cells in different generations of mouse airways.

Authors:  Yan Bai; Minsi Zhang; Michael J Sanderson
Journal:  Am J Respir Cell Mol Biol       Date:  2006-08-24       Impact factor: 6.914

5.  Value of inhaled corticosteroid therapy in long-term asthma management.

Authors:  Donald S Beam
Journal:  P T       Date:  2010-07

Review 6.  The case for impulse oscillometry in the management of asthma in children and adults.

Authors:  Stanley P Galant; Hirsh D Komarow; Hye-Won Shin; Salman Siddiqui; Brian J Lipworth
Journal:  Ann Allergy Asthma Immunol       Date:  2017-06       Impact factor: 6.347

7.  The augmented RIC model of the human respiratory system.

Authors:  Bill Diong; A Rajagiri; M Goldman; H Nazeran
Journal:  Med Biol Eng Comput       Date:  2009-01-31       Impact factor: 2.602

8.  Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study.

Authors:  C M Houghton; S J Langley; S D Singh; J Holden; A P Monici Preti; D Acerbi; G Poli; A Woodcock
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

9.  Association of recent exposure to ambient metals on fractional exhaled nitric oxide in 9-11 year old inner-city children.

Authors:  Maria José Rosa; Matthew S Perzanowski; Adnan Divjan; Steven N Chillrud; Lori Hoepner; Hanjie Zhang; Robert Ridder; Frederica P Perera; Rachel L Miller
Journal:  Nitric Oxide       Date:  2014-05-27       Impact factor: 4.427

10.  Evaluation of Mangosteen juice blend on biomarkers of inflammation in obese subjects: a pilot, dose finding study.

Authors:  Jay K Udani; Betsy B Singh; Marilyn L Barrett; Vijay J Singh
Journal:  Nutr J       Date:  2009-10-20       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.